ASCO GU 2022 VL

The State of Bipolar Androgen Therapy in Prostate Cancer - Emmanuel Antonarakis

Details
Joining Charles Ryan is Emmanuel Antonarakis to detail the present state of bipolar androgen therapy (BAT) and where the field going. Biographies: Emmanuel Antonarakis, MD, Clark Endowed Professor of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota Charles J. Ryan, MD , the President and Chief Executive Officer of The Prostate Cancer Foundation (PCF), the wor...

Identifying Unmet Needs in the Patient Journey in Prostate Cancer - Alicia Morgans

Details
Oliver Sartor is joined by Alicia Morgans to discuss her presentation at the GU ASCO 2022 Annual Meeting on the largest digital survey conducted in patients with prostate cancer, the initial results of an international survey of patients with prostate cancer. The goal of this survey was to map patient experiences, expectations, and attitudes, and to identify challenges and unmet needs in diagnosis...

Beyond PSMA - New Targets in Prostate Cancer - Tanya Dorff

Details
Tanya Dorff joins Alicia Morgans to discuss the highlights from her presentation at the 2022 GU ASCO Annual meeting focusing on new targets in prostate cancer beyond prostate-specific membrane antigen (PSMA). She highlights potential new targets including prostate stem cell antigen (PSCA), JNJ-75229414 is a KLK2 CAR T, and STEAP-1. Drs. Morgans and Dorff also discuss tumor heterogeneity and neuroe...

Treatment Considerations in Advanced Prostate Cancer - Bertrand Tombal

Details
Alicia Morgans is joined by Bertrand Tombal who provides a European perspective highlighting prostate cancer data we have seen so far this year starting with the ARASENS and PEACE-1 data. Dr. Tombal's discussion highlights key points for the community to focus on including the messages around maximal androgen blockade and PARP inhibitors. Biographies: Bertrand Tombal, MD, PhD, Chairman of the Depa...

Atezolizumab in Advanced Penile Cancer With or Without Radiotherapy, PERICLES - Hielke Martijn De Vries

Details
Hielke Martijn de Vries joins Alicia Morgans to discuss immunotherapy with or without radiation therapy for advanced penile cancer patients, the results of the PERICLES study. PERICLES is a phase II trial investigating atezolizumab +/- radiotherapy for advanced squamous cell carcinoma of the penis. Biographies: Hielke Martijn de Vries, Department of Urology, Netherlands Cancer Institute, Amsterdam...

Overall Response Rate After Immune-Checkpoint Inhibitor Initiation and Post-ICI PFS in Patients With Advanced Urothelial Carcinoma - Dimitrios Makrakis

Details
Petros Grivas is joined by Dimitrios Makrakis to discuss his multi-institutional retrospective cohort study of patients with advanced urothelial carcinoma (UC) who received platinum-based chemotherapy in the first line, followed by second-line immune checkpoint inhibitor (ICI). In this study, the timely question of how the duration of response to immune checkpoint inhibitor may be interpreted as p...

The First Neoadjuvant Trial Using Combination Immune Checkpoint Inhibitor and VEGF Inhibitor in Patients With Locally Advanced High-Risk RCC (NeoAvAx) – Axel Bex

Details
Axel Bex joins Alicia Morgans to discuss the results of the NeoAvAx trial examining neoadjuvant avelumab and axitinib following nephrectomy for patients who are at high risk for recurrence. The NeoAvAx trial tests the neoadjuvant use of a combination of the immune checkpoint inhibitor avelumab and the VEGF-inhibitor axitinib. Biographies: Axel Bex, MD, PhD, Urologic Surgeon, Royal Free London NHS...

Active Surveillance for Patients With Intermediate-Risk Prostate Cancer - Stacy Loeb

Details
Alicia Morgans is joined by Stacy Loeb to discuss her presentation at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium on the risks and the benefits of active surveillance in the intermediate-risk population. Over the last several years, there has been an increase in the utilization of active surveillance in the United States for patients with intermediate r...

Microbiome Research in Bladder Cancer - Laura Bukavina

Details
Ashish Kamat is joined by Laura Bukavina to discuss her work on the Microbiome of Bladder Cancer. Currently, we have little knowledge about the microbiome and bladder cancer. The research being done at Fox Chase and Case Western is comparing the beta diversity of bladder cancer patients compared to healthy controls to help think of ways to modulate the microbiome to improve the treatment of patien...

Antibody-Drug Conjugates in Advanced Urothelial Cancer: Clinical Perspective - Scott Tagawa

Details
Scott Tagawa joins Sam Chang to highlight the key topics of his discussion at the American Society for Clinical Oncology (ASCO) Genitourinary Cancer Symposium 2022. Dr. Tagawa provided a clinical perspective on antibody-drug conjugates in the treatment of urothelial carcinoma. Biographies: Scott T. Tagawa, MD, Associate Professor of Clinical Medicine, Clinical Urology, Medical Director, Genitourin...
email news signup